- Exenatide for adolescents with severe obesity yielded modest reductions in BMI and improvements in cholesterol levels and glucose tolerance in this randomized controlled trial.
Why this matters
- Pharmacological therapies for this population are limited.
- Compared with placebo, the exenatide group experienced reductions in (95% CIs):
- BMI: −0.83 kg/m2 (−1.68 to 0.01 kg/m2; P<.05>
- Percentage at BMI 95% percentile: −2.9% (−5.4% to −0.3%).
- Weight: −3.0 kg (−5.8 to −0.1 kg).
- Waist circumference: −3.2 cm (−5.8 to −0.7 cm).
- Subcutaneous adipose tissue: −552 cm3 (−989 to −114 cm3).
- 2-hour glucose during oral glucose tolerance test: −15.3 mg/dL (−27.5 to −3.1 mg/dL).
- Low-density lipoprotein cholesterol: −7.3 mg/dL (−14.2 to −0.4 mg/dL).
- Double-blind, placebo-controlled trial of 44 patients, ages 10-18 years randomly allocated to exenatide extended release (2 mg; n=22) or placebo (n=22) weekly subcutaneous injections.
- Funding: European Union Seventh Framework Programme; Regional Research Council in Uppsala‐Örebro, Sweden; others.
- Small numbers, trial duration of 6 months.